logo
Plus   Neg
Share
Email

Novartis : Type 2 Diabetes Study Shows Long-term Clinical Benefits

Novartis (NVS) said that five-year VERIFY study in type 2 diabetes demonstrated long-term clinical benefits of early combination treatment with Galvus and metformin.

The company noted that early combination treatment strategy with vildagliptin (Galvus) and metformin was superior to standard of care in newly diagnosed type 2 diabetes patients.

The company said it is committed to optimizing patient management of type 2 diabetes to achieve better glycemic control and favorable long-term clinical outcomes.

Additional pre-defined secondary analyses of the VERIFY study results are ongoing and data will be disclosed over the coming months at international and local medical congresses and in scientific journals, the company said.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Department of Transportation says it received lesser number of complaints from consumers about airline services in August. In August, DOT received 1,712 complaints about airline service from consumers, down 1.0% from the total of 1,730 filed in August 2018 and down 8.7% from the 1,875 received... Shares of Netflix Inc. (NFLX) jumped 7% in extended trading session Wednesday after the online-video streaming giant said it added more subscribers in the third quarter after a disappointing previous quarter. The company's third-quarter earnings topped Wall Street estimates, as revenues surged 31%. Netflix... Alcoa Corp. (AA), the largest producer of aluminum in the US, Wednesday posted a wider-than-expected loss for the third quarter, reflecting a drop in revenues as well as one-time charges related to two smelters in Spain. The company also announced a "portfolio review" of its smelting and refining capacity...
Follow RTT
>